Eli Lilly and Company (LLY)
Health Care43 articles
Price chart
Why is LLY moving?
NeutralJul 18Eli Lilly's (LLY) stock price has been rising, attributed to developments unrelated to its weight loss treatments. Specific figures regarding stock price changes or trading volumes were not provided. This surge signifies investor focus on alternative drivers for growth, indicating a potential shift in market sentiment. Understanding these underlying factors could be crucial for investors as they navigate Eli Lilly's performance in the volatile healthcare market.
Read the full story →Eli Lilly and Company (LLY) overview
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Eli Lilly and Company trades on the NYSE under the ticker symbol LLY. As of the most recent market data, the stock was priced around $1,179.11, up 0.85% on the session.
Over the past 52 weeks, LLY has traded between $623.78 and $1,249.45. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 41.8, a common gauge of how richly the market prices the company's earnings. Eli Lilly and Company also pays a dividend, currently yielding around 59.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch LLY
As one of the larger companies in the Health Care sector, Eli Lilly and Company is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch LLY for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest LLY news
Eli Lilly Stock Surge Driven by New Factors, Not Weight Loss
Eli Lilly's (LLY) stock price has been rising, attributed to developments unrelated to its weight loss treatments. Specific figures regarding stock price changes or trading volumes were not provided. This surge signifies investor focus on alternative drivers for growth, indicating a potential shift in market sentiment. Understanding these underlying factors could be crucial for investors as they navigate Eli Lilly's performance in the volatile healthcare market.
Read More: Eli Lilly Stock Surge Driven by New Factors, Not Weight Loss
Lilly Nears Acquisition Deal for AtaiBeckley Drugmaker
Eli Lilly is reportedly close to finalizing a deal to acquire Atai Bechkley, a company involved in developing psychedelic drugs. This acquisition could enhance Lilly's portfolio in the emerging field of mental health treatments. Though details regarding the financials of the deal are not disclosed, such strategic moves are essential for companies like Lilly (LLY) as they seek to capitalize on new therapeutic areas. The potential market impact could position Lilly favorably as the industry evolves towards more innovative drug solutions.
Read More: Lilly Nears Acquisition Deal for AtaiBeckley Drugmaker
IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions
The iShares Biotechnology ETF (IBB) has risen 51% over the last year and is up 16.06% year to date, compared to a 9.22% gain for the S&P 500. Eli Lilly (LLY) has announced four acquisitions in Q1 2026 and reported Q1 revenues of $19.80 billion, a 55.5% increase year over year. The company's Mounjaro revenue reached $8.66 billion, a 125% growth. Cramer expects an influx of deals in the biotech sector following changes in FDA leadership, making biotech an attractive sector for investors given current market conditions.
Read More: IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions
Lilly (LLY) to Present Alzheimer's Research at London Conference
Eli Lilly (LLY) announced it will present new research on Alzheimer's at a conference in London. This presentation is part of their ongoing efforts to advance treatments for Alzheimer's disease. Lilly's research could influence market perceptions significantly, especially regarding healthcare investments. The results from such studies are important for investors monitoring the pharmaceutical sector.
Read More: Lilly (LLY) to Present Alzheimer's Research at London Conference
IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
The iShares U.S. Pharmaceuticals ETF (IHE) has an expense ratio of 0.38% and a dividend yield of 1.62%, while the Invesco Pharmaceuticals ETF (PJP) has a higher expense ratio of 0.57% and a dividend yield of 0.96%. IHE holds 56 positions, heavily concentrated in Eli Lilly (NYSE:LLY) at 24.2% and Johnson & Johnson (NYSE:JNJ) at 20.3%. In contrast, PJP features 29 companies with Eli Lilly at 5.4%. Investors' choice between IHE and PJP hinges on their comfort with company-specific risks within the pharmaceutical sector.
Read More: IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Eli Lilly (LLY) and Regeneron (REGN) are among the first seven companies selected for the FDA's PreCheck pilot program aimed at accelerating reviews of new pharmaceutical manufacturing facilities. The initiative allows regulators to review facilities during construction, potentially saving companies up to 14 months in review time. Lilly's facility in Lebanon, Indiana, and Regeneron's $2 billion site in Saratoga Springs, New York, are included in the program. This effort targets domestic drug production and involves companies producing biologic drugs and genetic medicines.
Read More: Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Tesla (TSLA) Market Moves Amid Dow Jones Futures Analysis
Dow Jones futures are indicating potential volatility in the market. Eli Lilly (LLY) has shown significant gains, prompting discussions around strategic investment decisions. While specific trading volumes and percentages were not provided, the mention of market tipping points suggests a crucial moment for investors. Tesla (TSLA) is highlighted as a key focus in upcoming trading sessions, emphasizing its importance in the broader market context.
Read More: Tesla (TSLA) Market Moves Amid Dow Jones Futures Analysis
Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
Lilly's (LLY) obesity drug candidates are nearing significant milestones in clinical trials, which could have considerable market implications. Investors are particularly focused on the upcoming data release expected to influence the company's stock performance. The expected efficacy of these drugs could lead to a substantial increase in market share within the obesity treatment sector. As obesity rates rise globally, pharmaceuticals like those from Lilly are poised for rapid growth in demand.
Read More: Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
Cathie Wood Sells $26.65M Robinhood (HOOD), Buys $46.18M Eli Lilly
On June 18, Cathie Wood’s ARK Invest sold 275,572 shares of Robinhood (HOOD) worth $26.65 million and 239,267 shares of Roku (ROKU) valued at $33.01 million. The sales followed significant stock rallies driven by profit-taking after Robinhood's announcement of a 10% workforce cut and Roku's acquisition deal valued at $22 billion. Wood reinvested approximately $46.18 million into Eli Lilly (LLY) by acquiring 41,138 shares, indicating a shift towards new growth opportunities. This strategic repositioning highlights Wood's focus on potential upside stories rather than established rallies.
Read More: Cathie Wood Sells $26.65M Robinhood (HOOD), Buys $46.18M Eli Lilly
Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Wegovy continues to lead the GLP-1 market among weight-loss medications, despite competition from Eli Lilly's Foundayo. Specific market share percentages or sales figures were not provided. This dominance highlights Wegovy's strong brand recognition and patient preference in a growing sector. The competitive landscape for GLP-1 medications may impact market valuations for companies involved in this space, including Eli Lilly (LLY).
Read More: Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Eli Lilly (LLY) Acquires Vaccine Firms for $3.8 Billion Growth Strategy
Eli Lilly (LLY) reported approximately $12.8 billion in revenues for Q1 2026, with its key drugs Mounjaro and Zepbound experiencing year-over-year sales growth of 125% and 80%, respectively. The company has invested $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company to expand its presence in infectious diseases. Eli Lilly's current P/E ratio stands at 39x, significantly higher than the pharmaceutical sector average of 24x. This strategic move is seen as a way to diversify its portfolio as the patent protection on its GLP-1 drugs is time-limited.
Read More: Eli Lilly (LLY) Acquires Vaccine Firms for $3.8 Billion Growth Strategy
Eli Lilly (LLY) shares phase 3 data on weight loss drug retatrutide
Eli Lilly (LLY) released phase 3 clinical trial data for retatrutide, a triple agonist designed for weight loss. The drug demonstrated significant efficacy in reducing body weight among participants, but specific numerical results were not disclosed in the announcement. This development is crucial as it highlights LLY's commitment to expanding its product portfolio in the obesity treatment space. The market could respond positively if further details indicate strong potential for retatrutide in the pharmaceutical market.
Read More: Eli Lilly (LLY) shares phase 3 data on weight loss drug retatrutide
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Read More: CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
The iShares U.S. Pharmaceuticals ETF (IHE) has posted a 1-year return of 39.70% as of May 20, 2026, while the iShares Global Healthcare ETF (IXJ) reported a return of 10.00%. Both funds have similar expense ratios, with IHE at 0.38% and IXJ at 0.40%. IHE's assets under management (AUM) stand at $883.6 million, compared to IXJ's $3.6 billion. Additionally, IHE has a higher dividend yield of 1.70% versus IXJ's 1.50%, indicating potential advantages for investors favoring domestic pharmaceutical exposure.
Read More: IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
Eli Lilly (LLY) announced plans to acquire three companies for nearly $4 billion, intending to enhance its research efforts in infectious diseases. The acquisition includes Curevo for $1.5 billion, LimmaTech Biologics at $780 million, and Vaccine Company for $1.55 billion. Following this announcement, Eli Lilly's shares increased by 1.3% in premarket trading. The company's strategy emphasizes disease prevention at its source. These moves could impact the company's market position in the growing vaccine sector.
Read More: Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Leerink has reiterated its stock rating for Eli Lilly (LLY), highlighting the company's ongoing advancements in gene therapy. Although specific data points or numerical targets were not disclosed in the article, the emphasis on progress suggests potential future benefits for LLY stock. The continuation of this rating indicates confidence among analysts regarding LLY's pipeline competitiveness and market position. Observers might consider this signal a bullish indicator for LLY's potential in the evolving biopharmaceutical sector.
Read More: Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
Eli Lilly (LLY) announced that its next-generation obesity drug, retatrutide, successfully completed a late-stage trial, showing a significant weight loss of 28.3% on average over 80 weeks. Approximately 45% of 2,500 trial participants achieved 30% or more weight loss, and around 65% reached a BMI below 30. Analysts had anticipated retatrutide to outperform Lilly's current weight loss drug, Zepbound, which achieves about 20% to 22% weight loss. The expected sales for retatrutide could reach $3.8 billion by 2030, highlighting its potential impact in the growing weight loss and diabetes market, projected to value around $100 billion by that time.
Read More: Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Eli Lilly and Company (LLY) received a price target increase to $1,400 from $1,350 by Barclays following strong first-quarter results. Goldman Sachs reiterated a Buy rating with a target of $1,283, stating that the stock's recent weakness seems overblown. The company revised its 2026 full-year revenue guidance to $82-85 billion, indicating a 28% growth from 2025. Additionally, LLY's non-GAAP EPS is estimated between $35.50 and $37, higher than previous estimates, reflecting robust performance across its therapeutic areas.
Read More: Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) announced that patients taking the high-dose 7.2-milligram version of Wegovy lost an average of 27.7% of their weight over 72 weeks in a recent trial. This data was presented at the European Congress on Obesity and could assist Novo in enhancing its competitive position against Eli Lilly's (LLY) Zepbound, which has shown weight loss of over 20%. The previous highest dose of Wegovy (2.4 mg) resulted in a 17% average weight loss. Approximately 25% of patients in the higher dose trial experienced early treatment response, achieving significant weight loss early in the treatment cycle.
Read More: Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Pfizer (PFE) stock is down over 50% from its 2021 high as demand for COVID vaccines decreases. The company is facing headwinds, including upcoming patent cliffs that could lead to revenue declines for key drugs. Despite this, Pfizer maintains a 6.4% dividend yield, with management stating that supporting the dividend is a key corporate goal. The company has taken steps to pivot towards GLP-1 weight-loss drugs and continues to develop its portfolio in oncology and migraine treatments, which could improve its market position in the future.
Read More: Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
Eli Lilly and Co (NYSE:LLY) announced Q1 2026 results, with adjusted earnings per share at $8.55, exceeding analyst estimates of $6.66 to $6.97. Revenue reached $19.8 billion, surpassing expectations of $17.4 billion to $17.8 billion, indicating a 56% year-over-year increase. The company raised its 2026 revenue outlook to between $82 billion and $85 billion, up from $80 billion to $83 billion. This growth is primarily driven by increased prescription volumes for its GLP-1 medications, despite lower pricing realizations, and the recent FDA approval of Foundayo is expected to further expand access to treatments.
Read More: Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
Premarket trading saw significant movements with stocks like Meta and Amazon. Eli Lilly's (LLY) shares reportedly reacted to recent earnings reports, indicating a response to shifting market expectations. Caterpillar (CAT) is also in the spotlight, reflecting a broader interest in industrials amid changing economic conditions. These fluctuations are indicative of potential investor sentiment shifts and market impact as trading volumes adjust.
Read More: Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Eli Lilly (LLY) reported Q1 earnings of $8.55 per share and revenue of $19.80 billion, surpassing estimates of $6.66 and $17.62 billion, respectively. The company raised its 2026 revenue guidance to $82-$85 billion from $80-$83 billion. Mounjaro's revenue increased 125% to $8.66 billion, while Zepbound generated $4.16 billion in U.S. sales, an 80% year-over-year rise. With a strong 60.1% share of the U.S. obesity market, the robust demand for its products underscores Lilly's market position despite price pressures.
Read More: Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
Eli Lilly (LLY) reported sales of $12.9 billion from its GLP-1 drugs every three months. The company stated that the tirzepatide franchise had a strong quarter, indicating significant market demand. This growth reflects the increasing adoption of these drugs as part of diabetes treatment. The positive sales performance could impact investor sentiment and market positioning for LLY as it continues to expand in the pharmaceutical sector.
Read More: Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Novartis (NVS), Amgen (AMGN), and Eli Lilly (LLY) are conducting late-stage trials for drugs aimed at reducing lipoprotein(a) or Lp(a) levels to prevent heart attacks. Current experimental drugs are shown to reduce Lp(a) by over 80%. Consensus estimates suggest these drugs could generate annual sales of $5.6 billion by 2032. The first results from Novartis' Phase 3 Horizon trial are expected later this year, which will significantly influence the market potential of these therapies.
Read More: Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
Eli Lilly (LLY) announced plans to acquire Kelonia Therapeutics for approximately $7 billion, a move intended to strengthen its gene therapy pipeline. The company reported a year-over-year revenue increase of 43% and earnings per share growth of 51% during the fourth quarter. Its current forward-looking price-to-earnings (P/E) ratio stands at 40, below its five-year average of 56. With health spending growing by 7.2% from 2023 to 2024, managing competition in the weight-loss sector remains crucial for Lilly's future growth.
Read More: Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More: Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Read More: Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) market share drops to 56% in India as generics flood
Eli Lilly (LLY) saw its market share in India's GLP-1 weight-loss drug category decline to 56% in March from 61% in February, according to Pharmarack data. Meanwhile, Novo Nordisk (NVO) maintained a steady 25% market share despite the influx of generic semaglutide drugs following the expiration of its patent last month. The launch of 26 brands by 13 Indian generic companies is significantly impacting sales for Eli Lilly's higher-priced tirzepatide products. As generic options become more affordable, the competitive landscape for weight-loss treatment in India is changing rapidly, likely benefiting Novo Nordisk in the long run.
Read More: Eli Lilly (LLY) market share drops to 56% in India as generics flood
Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa
Eli Lilly and Company (LLY) received FDA approval for its weight loss pill, Foundayo, which can be taken without food or water restrictions, starting at $25 per month. The company also announced its acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on neurological treatments. These developments may enhance LLY's market position, particularly in the weight loss and neuroscience sectors. Investor sentiment is influenced by the dual impact of the weight loss pill and the strategic acquisition aimed at addressing complex medical conditions.
Read More: Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa
Eli Lilly (LLY) Acquires Centessa for $7.8 Billion
Eli Lilly and Company (LLY) announced the acquisition of Centessa for $7.8 billion, with analyst estimates suggesting a market potential for Centessa's drugs of up to $20 billion. The company's stock rose 4.6% over the past five days and is up 18.6% year-over-year, despite a year-to-date decline of 13.4%. Additionally, on April 1, the FDA approved LLY's GLP-1 weight loss pill, Foundayo. Eli Lilly's aggressive investment marks its commitment to tackling challenging medical issues, which may enhance its market position moving forward.
Read More: Eli Lilly (LLY) Acquires Centessa for $7.8 Billion
Eli Lilly (LLY) Stock Rating Reiterated After Obesity Drug Approval
Leerink has reiterated its stock rating for Eli Lilly (LLY) following the approval of the company's obesity drug. This approval is significant as it may impact the company's market position and revenue outlook. Eli Lilly's performance in the market is closely watched due to its developments in pharmaceuticals. Investors may see fluctuations in stock price as more information about the drug’s market introduction becomes available.
Read More: Eli Lilly (LLY) Stock Rating Reiterated After Obesity Drug Approval
Eli Lilly (LLY) Obesity Pill Foundayo Receives FDA Approval
Eli Lilly's (LLY) GLP-1 obesity pill, Foundayo, has received approval from the U.S. FDA. This approval is significant as it paves the way for Eli Lilly to enter the competitive weight loss drug market, where it will face off against rival Novo Nordisk. The successful approval could impact market dynamics and influence trading volumes for both companies. The development is expected to drive Eli Lilly's growth in the pharmaceutical sector and could potentially affect pricing strategies for obesity treatments.
Read More: Eli Lilly (LLY) Obesity Pill Foundayo Receives FDA Approval
Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
Eli Lilly (LLY) received US approval for its weight-loss drug, Foundayo. This approval introduces competition in the oral obesity drug market, particularly against Novo Nordisk. The specifics of the approval, including safety and efficacy data, have not been disclosed in this article. The entry of Foundayo may influence market dynamics as both companies vie for market share in the oral obesity treatment space.
Read More: Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
Eli Lilly (LLY) Receives FDA Approval for Obesity Pill
Eli Lilly (LLY) has received FDA approval for its obesity treatment pill, a significant milestone for the company. This approval may impact Eli Lilly's market position and sales potential in the competitive obesity treatment sector. FDA approvals are critical for pharmaceutical companies as they can lead to increased revenue growth. The approval could bolster investor confidence and influence stock performance in coming sessions.
Read More: Eli Lilly (LLY) Receives FDA Approval for Obesity Pill
Eli Lilly (LLY) GLP-1 Pill Approved: Launching Foundayo for Weight Loss
Eli Lilly's (LLY) GLP-1 pill, Foundayo, has received FDA approval and will begin shipping via LillyDirect, available in pharmacies
Read More: Eli Lilly (LLY) GLP-1 Pill Approved: Launching Foundayo for Weight Loss
Lilly (LLY) Wins FDA Approval for Oral Obesity Drug Foundayo
Lilly (LLY) has received FDA approval for its oral obesity drug, Foundayo. This approval may provide Lilly a competitive edge in the obesity treatment market, which has seen increasing demand. The financial impact of this approval could potentially enhance Lilly's revenue from obesity-related therapies. The wider implications for market dynamics in pharmaceutical and healthcare sectors will depend on the drug's acceptance and sales performance.
Read More: Lilly (LLY) Wins FDA Approval for Oral Obesity Drug Foundayo
Eli Lilly (LLY) stock surges after FDA obesity pill approval
Eli Lilly (LLY) experienced a significant stock surge following the FDA's approval of its obesity treatment. This approval marks a pivotal moment for LLY as it expands its product offerings in the pharmaceutical market. The exact percentage increase or trading volume was not specified in the article. The approval is likely to create a positive impact on LLY's market position and potential revenue, reflecting investor confidence in the company's future growth.
Read More: Eli Lilly (LLY) stock surges after FDA obesity pill approval
Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders
Lilly (LLY) announced the acquisition of Centessa Pharmaceuticals, focusing on OX2R drug candidates for sleep disorders. This strategic move aims to enhance LLY's portfolio in the sleep medicine market, which has seen increasing demand. Financial terms of the deal were not disclosed, but the acquisition is anticipated to bolster LLY's research and development capabilities. The market impact could reflect positively on LLY's stock as they expand their therapeutic offerings.
Read More: Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders
Stocks Soar on Hopes of Iran War Resolution Amid Market Optimism
Limited data available — the article discusses the rise in stock prices linked to hopes for a resolution regarding the Iran conflict. Specific data points regarding stock movement or market figures were not provided. Additionally, it mentions Eli Lilly's (LLY) advancements in tackling sleep disorders, but lacks quantifiable metrics or market implications. As such, the potential market direction remains unclear.
Read More: Stocks Soar on Hopes of Iran War Resolution Amid Market Optimism
Centessa (CNTA) Downgraded After Lilly Deal Announcement
Wolfe Research downgraded Centessa Pharmaceuticals (CNTA) following its agreement with Eli Lilly (LLY) for their experimental Alzheimer’s drug. The downgrade is a response to potential market shifts resulting from this partnership. Investors may see fluctuations in CNTA's stock performance due to changing perceptions around the collaboration's impact. This reflects broader trends in the pharmaceutical sector, especially in biopharmaceutical partnerships.
Read More: Centessa (CNTA) Downgraded After Lilly Deal Announcement
Eli Lilly (LLY) acquires Centessa for up to $7.8 billion
Eli Lilly (LLY) announced its acquisition of Centessa Pharmaceuticals in a deal valued up to $7.8 billion, aiming to diversify into sleep disorder treatments. Centessa's lead therapy targets excessive daytime sleepiness and is currently in mid-stage studies. Lilly's offer includes $38 per share in cash, a 37.8% premium, and a contingent value right worth about $1.5 billion. Centessa's shares rose 46% in premarket trading following the announcement, which is set to close in the third quarter.
Read More: Eli Lilly (LLY) acquires Centessa for up to $7.8 billionMore Health Care stocks
Frequently asked questions
Is Eli Lilly and Company in the S&P 500?
Yes. Eli Lilly and Company (LLY) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is LLY in?
Eli Lilly and Company is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest LLY news?
This page collects recent Eli Lilly and Company (LLY) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Eli Lilly and Company's stock price?
As of the most recent market data, Eli Lilly and Company (LLY) traded at approximately $1,179.11. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is LLY's P/E ratio?
LLY trades at a trailing price-to-earnings ratio of about 41.8. The P/E ratio compares a company's share price to its earnings per share.